Biogtuss

Description

BioGtussNFLabel is a pharmaceutical product formulated for specific therapeutic applications. The product's precise chemical composition and structural characteristics are proprietary. It is designed to meet the rigorous standards of pharmaceutical quality and efficacy. The formulation includes a combination of active and inactive ingredients, which contribute to its intended use. The product is available in a dosage form suitable for administration, ensuring optimal delivery and absorption. Its appearance is consistent with industry standards for similar formulations, facilitating identification and use in clinical settings.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritations, which may occur due to the common cold or inhaled irritants. It aids in loosening phlegm (mucus) and thinning bronchial secretions, thereby making coughs more productive. Additionally, this drug provides temporary relief from nasal congestion resulting from the common cold.

Limitations of use include the absence of data regarding teratogenic or nonteratogenic effects. Therefore, healthcare professionals should exercise caution and consider individual patient circumstances when prescribing this medication.

Dosage and Administration

Adults and children over 12 years of age are advised to take 1 teaspoonful (5 mL) every 6 to 8 hours as needed. For children aged 6 to under 12 years, the recommended dosage is 1/2 teaspoonful (2.5 mL) every 6 to 8 hours.

It is important to note that for children under 6 years of age, consultation with a healthcare professional is required prior to use.

Healthcare professionals should ensure that patients do not exceed 6 doses within a 24-hour period to avoid potential overdose.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

Patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, the product should not be used for at least 2 weeks after discontinuing an MAOI. If there is uncertainty regarding the presence of an MAOI in any current prescription, patients are advised to consult their healthcare provider or pharmacist prior to use.

Healthcare professionals should advise patients to seek medical guidance before using this product if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, difficulty urinating due to prostate gland enlargement, a cough with excessive phlegm, or a persistent or chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema.

Furthermore, patients should consult a healthcare provider before use if they are currently taking sedatives, tranquilizers, or any medications for depression, including MAOIs.

Patients are instructed to discontinue use and consult a healthcare professional if they experience nervousness, dizziness, or sleeplessness. Additionally, if a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a headache that lasts, these symptoms may indicate a serious condition requiring medical evaluation.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious warnings include the contraindication of use in patients currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing such medication, as this may lead to severe interactions.

Before initiating treatment, patients with pre-existing conditions should consult a healthcare professional if they have heart disease, high blood pressure, thyroid disease, diabetes, difficulty urinating due to an enlarged prostate gland, or a cough that produces excessive phlegm. Additionally, individuals with a persistent or chronic cough, such as those caused by smoking, asthma, chronic bronchitis, or emphysema, should seek medical advice prior to use.

Patients are advised to discontinue use and consult a healthcare provider if they experience nervousness, dizziness, or sleeplessness. Furthermore, if a cough persists for more than seven days, recurs, or is accompanied by fever, rash, or headache, these symptoms may indicate a serious underlying condition that requires medical evaluation.

Drug Interactions

The concomitant use of this medication with monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this medication if they are currently taking a prescription MAOI, which includes certain drugs prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, it is advised to avoid this medication for a period of two weeks following the discontinuation of an MAOI.

Healthcare providers should be consulted prior to the use of this medication in patients who are taking sedatives, tranquilizers, or other drugs for depression, including MAOIs. Monitoring for potential interactions and adverse effects is recommended in these cases.

Packaging & NDC

Below are the non-prescription pack sizes of Biogtuss (dextromethorphan, guaifenesin, phenylephrine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may take 1/2 teaspoonful (2.5 mL) every 6-8 hours. For children under 6 years of age, it is advised to consult a doctor before use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with the use of this drug during pregnancy and lactation. The safety of this medication in pregnant women has not been established, and therefore, caution is advised.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions indicated for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols tailored to the substance involved. Continuous assessment and supportive measures should be prioritized to ensure patient safety and mitigate potential complications associated with overdose.

Nonclinical Toxicology

If pregnant or breast-feeding, it is advised to consult a doctor before use. There are no specific non-teratogenic effects or nonclinical toxicology details available. Additionally, no specific information regarding animal pharmacology and toxicology has been provided.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions associated with the use of BIOGTUSS NF: nervousness, dizziness, and sleeplessness. These reactions have been reported voluntarily or through surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is important to emphasize the potential risks associated with overdose. In the event of an accidental overdose, patients should be instructed to seek medical advice immediately or contact a Poison Control Center for assistance. This guidance is crucial to ensure patient safety and appropriate management of any adverse situations.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and protected from light to prevent degradation. After opening, the product should be discarded to ensure safety and efficacy. Additionally, it is essential to keep the product out of reach of children to prevent accidental ingestion.

Additional Clinical Information

The medication is administered orally. For adults and children over 12 years of age, the recommended dosage is 1 teaspoonful (5 mL) every 6-8 hours. For children aged 6 to under 12 years, the dosage is 1/2 teaspoonful (2.5 mL) every 6-8 hours. It is advised that parents or guardians consult a doctor before administering the medication to children under 6 years of age.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Biogtuss, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)